OTCMKTS:RNUGF - ReNeuron Group Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 06/19/2019 04:00 PM ET)
Today's Range
Now: $3.07
50-Day Range
MA: $3.52
52-Week Range
Now: $3.07
Volume2,581 shs
Average Volume182 shs
Market Capitalization$97.17 million
P/E RatioN/A
Dividend YieldN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. Read More…

Industry, Sector and Symbol

Industry Private households
Previous SymbolNASDAQ:RNUGF



Sales & Book Value

Annual Sales$60,000.00
Book Value$1.54 per share



Market Cap$97.17 million
Next Earnings Date7/18/2019 (Estimated)
OptionableNot Optionable

Receive RNUGF News and Ratings via Email

Sign-up to receive the latest news and ratings for RNUGF and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group (OTCMKTS:RNUGF) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the OTCMKTS under the ticker symbol "RNUGF."

When is ReNeuron Group's next earnings date?

ReNeuron Group is scheduled to release their next quarterly earnings announcement on Thursday, July 18th 2019. View Earnings Estimates for ReNeuron Group.

Has ReNeuron Group been receiving favorable news coverage?

Headlines about RNUGF stock have been trending somewhat negative on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ReNeuron Group earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include ReNeuron Group (RENE), Centamin (CEY), Oxford BioMedica (OXB), Premaitha Health (NIPT), Immune Design (IMDZ), Adobe (ADBE), AcelRx Pharmaceuticals (ACRX), Vodafone Group (VOD), UK Oil & Gas (UKOG) and GB Group (GBG).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

How do I buy shares of ReNeuron Group?

Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ReNeuron Group's stock price today?

One share of RNUGF stock can currently be purchased for approximately $3.07.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of $97.17 million and generates $60,000.00 in revenue each year. The company earns $-23,360,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. ReNeuron Group employs 62 workers across the globe.View Additional Information About ReNeuron Group.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is http://www.reneuron.com/.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-0-20-3819-8400.

MarketBeat Community Rating for ReNeuron Group (OTCMKTS RNUGF)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RNUGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNUGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Featured Article: What is a short straddle?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel